• Skip to primary navigation
  • Skip to content
  • Skip to footer
CardioCell

CardioCell

Breakthrough Cardiovascular Technology

  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Our Stem Cells
    • Manufacturing
    • Quality Control
    • Exclusive License
  • Clinical Trials
    • Overview
    • Chronic Heart Failure
    • Heart Failure in Patients With Left Ventricular Assist Devices
    • Acute Myocardial Infarction
  • News
    • Press Releases
    • Media Coverage
    • Publications
  • Events
  • LinkedIn

CardioCell offers bright spot in stem cell development

August 29, 2016

News


Aug 29, 2016

CardioCell offers bright spot in stem cell development

CIVE
CardioCell reported positive Phase II data for its intravenous stem cell therapy for the treatment of chronic heart failure at the European Society of Cardiology meeting in Rome on Sunday.
The study represented the first positive trial of IV ischemia-tolerant mesenchymal stem cells (itMSCs) in patients with chronic heart failure, after several other companies have failed in the space. READ FULL ARTICLE

Media Coverage,  News

Reader Interactions

Footer

About Us

  • Overview
  • Board of Directors
  • Scientific Advisory Board

Technology

  • Our Stem Cells
  • Manufacturing
  • Quality Control
  • Exclusive License

Clinical Trials

  • Overview
  • Chronic Heart Failure
  • Heart Failure in Patients With Left Ventricular Assist Devices
  • Acute Myocardial Infarction
<section id="bpfwp_contact_card_widget-1" class="widget widget_bpfwp_contact_card_widget"><div class="widget-wrap"><h3 class="widgettitle widget-title">Contact</h3>
info@stemcardiocell.com
</div></section>

Copyright © 2022 · Business Pro Theme on Genesis Framework · WordPress · Log in